http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-32985-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e9445e5e3626f36e932c6451a928250
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D203-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-46
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D203-24
filingDate 1969-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1974-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber IE-32985-B1
titleOfInvention Process for the production of new sulphanilamide derivatives
abstract 1,263,561. Imidazolidine derivatives. J. R. GEIGY A.G. 14 March, 1969 [14 March, 1968 (2)], No. 13513/69. Heading C2C. Novel Compounds I (including salts thereof) wherein R 1 signifies alkyl or alkenyl of at most 5 carbons or an optionally alkyl-substituted cycloalkyl or cycloalkenyl group or a cycloalkyl-alkyl or cycloalkenyl-alkyl group of at most 7 carbons and R 2 is Me or Et, are obtained: (a) by reacting a Compound II (R 3 signifies H, Me, allyl, aryldiaryl- or triarylmethyl and X signifies NH 2 or a group which can be converted into NH 2 by hydrolysis, reduction or reductive cleavage) with a reactive cyanic acid derivative; (b) by reacting a Compound III with a nitrile, R 1 NH.CN or with an alkali or alkaline earth metal salt thereof; (c) by reducing a Compound V (R 1 <SP>1</SP> signifies C 3-5 alkenyl or C 5-7 cycloalkenyl); or (d) by reacting a functional derivative of a sulphonic acid VI with an imidazoline VII (also described as the hydrobromide) Compounds II, III and VII are in general prepared by standard methods. Intermediates to Compounds I, e.g. compounds wherein in place of NH 2 in I there is an MeCONH- group may be produced by methods (a) to (d). N - Tert. butyl - (2 - benzylamino) - propionamide (also described as the hydrochloride), obtained by the interaction of benzylamine and N - tert. - butyl - 2 - chloro - propionamide, reacts with lithium aluminium hydride to afford N<SP>1</SP>- tert.-butyl-N<SP>2</SP>-benzyl-1,2-propane-diamine; the diamine is debenzylated to give N<SP>1</SP>-tert.-butyl- 1,2 - propane - diamine dihydrobromide. The following related compounds are also described: N-butyl-2-benzylamino-propionamide and -butyramide, N<SP>1</SP>-butyl-N<SP>2</SP>-benzyl-1,2-propanediamine and -1,2-butanediamine,and N<SP>1</SP>-butyl-1,2-propane diamine and -1,2-butane-diamine. N-Butyl-andbenzyl-2-chloro-propionamides are obtained by reacting 2-chloro-propionyl chloride with butyl amine or benzylamine (N-butyl-2-chloro-butyramide is similarly obtained); N-benzyl-2-tert.- butylamino -propionamide, N<SP>1</SP>-benzyl-N<SP>2</SP>-tert.- butyl-1,2-propanediamine and N<SP>2</SP>-tert.-butyl-1,2- propane diamine hydrobromide are also described. Pharmaceutical preparations showing hypoglycaemic action contain I as active-ingredient; administration may be orally or parenterally.n[GB1263561A]
priorityDate 1968-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID43112472
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154113564
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419484514
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID431972570
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409627861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559198
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419545847
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID540
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID260
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID111019
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419585978
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8007
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449445756
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1100
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID423247736
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410470922
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID75467
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5333
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419488072
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68156
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7504
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419502284
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393352
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410932322

Total number of triples: 40.